» Create a New Account » Forgot Your Password? » User Login
Browse Articles
Published Articles
Articles in Press
Journal Menu
About this Journal
Article Processing Charges
Author Guidelines
Bibliographic Information
Contact Information
Editorial Board
Reviewer Guidelines
Reviewers Acknowledgment
Abstract
Full-Text HTML
Full-Text PDF
Linked References
How to Cite this Article
Reviewer Evaluations 
Scholarly Research Exchange
Volume 2009 (2009), Article ID 173039
doi:10.3814/2009/173039
Review Article

Searching Genes Encoding Leishmania Antigens for Diagnosis and Protection

Manuel Soto,1 Laura Ramírez,1 Miguel A. Pineda,1 Victor M. González,2 Petter F. Entringer,3 Camila Indiani de Oliveira,3 Ivan P. Nascimento,3 Ana P. Souza,3 Laura Corvo,1 Carlos Alonso,1 Pedro Bonay,1 Claudia Brodskyn,3 Aldina Barral,3 Manoel Barral-Netto,3 and Salvador Iborra4
1Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, CSIC-UAM, Facultad de Ciencias, Universidad Autónoma de Madrid, 28049 Madrid, Spain
2Departamento de Bioquímica-Investigación, Hospital Ramón y Cajal, 28034 Madrid, Spain
3Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz (FIOCRUZ), Rua Waldemar Falcao, 121 Candeal, 40296-710 Salvador, BA, Brazil
4Unidad de Inmunología Viral, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Crta. Majadahonda Pozuelo Km 2, Madrid 28220, Spain
  • Received 2009-01-12
  • Revised 2009-04-17
  • Accepted 2009-05-14

References

  1. B. L. Herwaldt, “Leishmaniasis,” The Lancet, vol. 354, no. 9185, pp. 1191–1199, 1999.
  2. M. Gramiccia and L. Gradoni, “The current status of zoonotic leishmaniases and approaches to disease control,” International Journal for Parasitology, vol. 35, no. 11-12, pp. 1169–1180, 2005.
  3. G. M. Santos-Gomes, R. Rosa, C. Leandro, S. Cortes, P. Romão, and H. Silveira, “Cytokine expression during the outcome of canine experimental infection by Leishmania infantum,” Veterinary Immunology and Immunopathology, vol. 88, no. 1-2, pp. 21–30, 2002.
  4. L. Gradoni, “An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine,” Veterinary Parasitology, vol. 100, no. 1-2, pp. 87–103, 2001.
  5. D. McMahon-Pratt and J. Alexander, “Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease?,” Immunological Reviews, vol. 201, no. 1, pp. 206–224, 2004.
  6. H. D. F. H. Schallig and L. Oskam, “Molecular biological applications in the diagnosis and control of leishmaniasis and parasite identification,” Tropical Medicine and International Health, vol. 7, no. 8, pp. 641–651, 2002.
  7. K. Kar, “Serodiagnosis of leishmaniasis,” Critical Reviews in Microbiology, vol. 21, no. 2, pp. 123–152, 1995.
  8. J. Kubar and K. Fragaki, “Recombinant DNA-derived Leishmania proteins: from the laboratory to the field,” The Lancet Infectious Diseases, vol. 5, no. 2, pp. 107–114, 2005.
  9. R. N. Coler and S. G. Reed, “Second-generation vaccines against leishmaniasis,” Trends in Parasitology, vol. 21, no. 5, pp. 244–249, 2005.
  10. E. Handman, “Leishmaniasis: current status of vaccine development,” Clinical Microbiology Reviews, vol. 14, no. 2, pp. 229–243, 2001.
  11. F. Modabber, “Vaccines against leishmaniasis,” Annals of Tropical Medicine and Parasitology, vol. 89, pp. 83–88, 1995.
  12. C. L. Greenblatt, “The present and future of vaccination for cutaneous leishmaniasis,” Progress in Clinical and Biological Research, vol. 47, pp. 259–285, 1980.
  13. O. I. Kellina, “Problem and current lines in investigations on the epidemiology of leishmaniasis and its control in the U.S.S.R,” Bulletin de la Societe de Pathologie Exotique et de ses Filiales, vol. 74, no. 3, pp. 306–318, 1981.
  14. C. B. Palatnik, R. Borojevic, J. O. Previato, and L. Mendonça-Previato, “Inhibition of Leishmania donovani promastigote internalization into murine macrophages by chemically defined parasite glycoconjugate ligands,” Infection and Immunity, vol. 57, no. 3, pp. 754–763, 1989.
  15. C. B. Palatnik-de-Sousa, E. M. Gomes, E. Paraguai-de-Souza, M. Palatnik, K. Luz, and R. Borojevic, “Leishmania donovani: titration of antibodies to the fucose-mannose ligand as an aid in diagnosis and prognosis of visceral leishmaniasis,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 89, no. 4, pp. 390–393, 1995.
  16. G. P. Borja-Cabrera, V. O. Da Silva, R. T. Da Costa, et al., “The fucose-mannose ligand-ELISA in the diagnosis and prognosis of canine visceral leishmaniasis in Brazil,” The American Journal of Tropical Medicine and Hygiene, vol. 61, no. 2, pp. 296–301, 1999.
  17. L. E. Parra, G. P. Borja-Cabrera, F. N. Santos, L. O. P. Souza, C. B. Palatnik-de-Sousa, and I. Menz, “Safety trial using the Leishmune® vaccine against canine visceral leishmaniasis in Brazil,” Vaccine, vol. 25, no. 12, pp. 2180–2186, 2007.
  18. C. B. Palatnik-de-Sousa, H. S. Dutra, and R. Borojevic, “Leishmania donovani surface glycoconjugate GP36 is the major immunogen component of the Fucose-Mannose Ligand (FML),” Acta Tropica, vol. 53, no. 1, pp. 59–72, 1993.
  19. J.-L. Lemesre, P. Holzmuller, M. Cavaleyra, R. B. Gonçalves, G. Hottin, and G. Papierok, “Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes,” Vaccine, vol. 23, no. 22, pp. 2825–2840, 2005.
  20. J.-L. Lemesre, P. Holzmuller, R. B. Gonçalves, et al., “Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial,” Vaccine, vol. 25, no. 21, pp. 4223–4234, 2007.
  21. R. Rosa, O. R. Rodrigues, C. Marques, and G. M. Santos-Gomes, “Leishmania infantum: soluble proteins released by the parasite exert differential effects on host immune response,” Experimental Parasitology, vol. 109, no. 2, pp. 106–114, 2005.
  22. R. Rosa, C. Marques, O. R. Rodrigues, and G. M. Santos-Gomes, “Immunization with Leishmania infantum released proteins confers partial protection against parasite infection with a predominant Th1 specific immune response,” Vaccine, vol. 25, no. 23, pp. 4525–4532, 2007.
  23. L. L. Button and W. R. McMaster, “Molecular cloning of the major surface antigen of Leishmania,” Journal of Experimental Medicine, vol. 167, no. 2, pp. 724–729, 1988.
  24. K. L. Lohman, P. J. Langer, and D. McMahon-Pratt, “Molecular cloning and characterization of the immunologically protective surface glycoprotein GP46/M-2 of Leishmania amazonensis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 21, pp. 8393–8397, 1990.
  25. A. Jardim, S. Hanson, B. Ullman, W. D. McCubbin, C. M. Kay, and R. W. Olafson, “Cloning and structure-function analysis of the Leishmania donovani kinetoplastid membrane protein-11,” Biochemical Journal, vol. 305, part 1, pp. 315–320, 1995.
  26. C. E. Clayton, “Life without transcriptional control? From fly to man and back again,” The EMBO Journal, vol. 21, no. 8, pp. 1881–1888, 2002.
  27. J. E. Donelson, M. J. Gardner, and N. M. El-Sayed, “More surprises from Kinetoplastida,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 6, pp. 2579–2581, 1999.
  28. J. R. Webb, A. Campos-Neto, P. J. Ovendale, et al., “Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family,” Infection and Immunity, vol. 66, no. 7, pp. 3279–3289, 1998.
  29. B. Yahiaoui, M. Loyens, A. Taibi, R. Schöneck, J. F. Dubremetz, and M. A. Ouaissi, “Characterization of a Leishmania antigen associated with cytoplasmic vesicles resembling endosomal-like structure,” Parasitology, vol. 107, part 5, pp. 497–507, 1993.
  30. P. J. Murray, T. W. Spithill, and E. Handman, “The PSA-2 glycoprotein complex of Leishmania major is a glycosylphosphatidylinositol-linked promastigote surface antigen,” The Journal of Immunology, vol. 143, no. 12, pp. 4221–4226, 1989.
  31. L. Quijada, J. M. Requena, M. Soto, et al., “Mapping of the linear antigenic determinants of the Leishmania infantum Hsp70 recognized by leishmaniasis sera,” Immunology Letters, vol. 52, no. 2-3, pp. 73–79, 1996.
  32. M. Soto, J. M. Requena, and C. Alonso, “Isolation, characterization and analysis of the expression of the Leishmania ribosomal PO protein genes,” Molecular and Biochemical Parasitology, vol. 61, no. 2, pp. 265–274, 1993.
  33. M. Soto, J. M. Requena, M. Garcia, L. C. Gomez, I. Navarrete, and C. Alonso, “Genomic organization and expression of two independent gene arrays coding for two antigenic acidic ribosomal proteins of Leishmania,” The Journal of Biological Chemistry, vol. 268, no. 29, pp. 21835–21843, 1993.
  34. M. Soto, J. M. Requena, L. C. Gomez, I. Navarrete, and C. Alonso, “Molecular characterization of a Leishmania donovani infantum antigen identified as histone H2A,” European Journal of Biochemistry, vol. 205, no. 1, pp. 211–216, 1992.
  35. M. Soto, J. M. Requena, G. Morales, and C. Alonso, “The Leishmania infantum histone H3 possesses an extremely divergent N-terminal domain,” Biochimica et Biophysica Acta, vol. 1219, no. 2, pp. 533–535, 1994.
  36. S. O. Angel, J. M. Requena, M. Soto, D. Criado, and C. Alonso, “During canine leishmaniasis a protein belonging to the 83-kDa heat-shock protein family elicits a strong humoral response,” Acta Tropica, vol. 62, no. 1, pp. 45–56, 1996.
  37. J. MacFarlane, M. L. Blaxter, R. P. Bishop, M. A. Miles, and J. M. Kelly, “Identification and characterisation of a Leishmania donovani antigen belonging to the 70-kDa heat-shock protein family,” European Journal of Biochemistry, vol. 190, no. 2, pp. 377–384, 1990.
  38. J. M. Burns, Jr., J. M. Scott, E. M. Carvalho, et al., “Characterization of a membrane antigen of Leishmania amazonensis that stimulates human immune responses,” The Journal of Immunology, vol. 146, no. 2, pp. 742–748, 1991.
  39. Y. A. Skeiky, J. A. Guderian, D. R. Benson, et al., “A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12,” Journal of Experimental Medicine, vol. 181, no. 4, pp. 1527–1537, 1995.
  40. Y. A. Skeiky, D. R. Benson, J. A. Guderian, et al., “Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans,” Infection and Immunity, vol. 63, no. 10, pp. 4105–4114, 1995.
  41. J. R. Webb, D. Kaufmann, A. Campos-Neto, and S. G. Reed, “Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis,” The Journal of Immunology, vol. 157, no. 11, pp. 5034–5041, 1996.
  42. N. Santarém, R. Silvestre, J. Tavares, et al., “Immune response regulation by Leishmania secreted and nonsecreted antigens,” Journal of Biomedicine and Biotechnology, vol. 2007, Article ID 85154, 10 pages, 2007.
  43. J. M. Requena, C. Alonso, and M. Soto, “Evolutionarily conserved proteins as prominent immunogens during Leishmania infections,” Parasitology Today, vol. 16, no. 6, pp. 246–250, 2000.
  44. F. Y. Liew and C. A. O'Donnell, “Immunology of Leishmaniasis,” Advances in Parasitology, vol. 32, pp. 161–259, 1993.
  45. J. M. Requena, S. Iborra, J. Carrión, C. Alonso, and M. Soto, “Recent advances in vaccines for leishmaniasis,” Expert Opinion on Biological Therapy, vol. 4, no. 9, pp. 1505–1517, 2004.
  46. R. M. Locksley and J. A. Louis, “Immunology of leishmaniasis,” Current Opinion in Immunology, vol. 4, no. 4, pp. 413–418, 1992.
  47. P. Scott, P. Caspar, and A. Sher, “Protection against Leishmania major in BALB/c mice by adoptive transfer of a T cell clone recognizing a low molecular weight antigen released by promastigotes,” The Journal of Immunology, vol. 144, no. 3, pp. 1075–1079, 1990.
  48. E. Mougneau, F. Altare, A. E. Wakil, et al., “Expression cloning of a protective Leishmania antigen,” Science, vol. 268, no. 5210, pp. 563–566, 1995.
  49. P. Probst, E. Stromberg, H. W. Ghalib, et al., “Identification and characterization of T cell-stimulating antigens from Leishmania by CD4 T cell expression cloning,” The Journal of Immunology, vol. 166, no. 1, pp. 498–505, 2001.
  50. S. Gurunathan, D. M. Klinman, and R. A. Seder, “DNA vaccines: immunology, application, and optimization∗,” Annual Review of Immunology, vol. 18, pp. 927–974, 2000.
  51. P. M. Smooker, A. Rainczuk, N. Kennedy, and T. W. Spithill, “DNA vaccines and their application against parasites—promise, limitations and potential solutions,” Biotechnology Annual Review, vol. 10, pp. 189–236, 2004.
  52. D. Piedrafita, D. Xu, D. Hunter, R. A. Harrison, and F. Y. Liew, “Protective immune responses induced by vaccination with an expression genomic library of Leishmania major,” The Journal of Immunology, vol. 163, no. 3, pp. 1467–1472, 1999.
  53. P. C. Melby, G. B. Ogden, H. A. Flores, et al., “Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library,” Infection and Immunity, vol. 68, no. 10, pp. 5595–5602, 2000.
  54. C. B. Stober, U. G. Lange, M. T. M. Roberts, et al., “From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine Leishmania major infection,” Vaccine, vol. 24, no. 14, pp. 2602–2616, 2006.
  55. N. J. Fasel, D. C. Robyr, J. Mauel, and T. A. Glaser, “Identification of a histone H1-like gene expressed in Leishmania major,” Molecular and Biochemical Parasitology, vol. 62, no. 2, pp. 321–324, 1993.
  56. R. M. R. Coulson and D. F. Smith, “Isolation of genes showing increased or unique expression in the infective promastigotes of Leishmania major,” Molecular and Biochemical Parasitology, vol. 40, no. 1, pp. 63–75, 1990.
  57. H. Charest and G. Matlashewski, “Developmental gene expression in Leishmania donovani: differential cloning and analysis of an amastigote-stage-specific gene,” Molecular and Cellular Biology, vol. 14, no. 5, pp. 2975–2984, 1994.
  58. B. Yahiaoui, A. Taibi, and A. Ouaissi, “A Leishmania major protein with extensive homology to silent information regulator 2 of Saccharomyces cerevisiae,” Gene, vol. 169, no. 1, pp. 115–118, 1996.
  59. Y. Goto, R. F. Howard, A. Bhatia, et al., “Distinct antigen recognition pattern during zoonotic visceral leishmaniasis in humans and dogs,” Veterinary Parasitology, vol. 160, no. 3-4, pp. 215–220, 2009.
  60. R. A. Frye, “Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins,” Biochemical and Biophysical Research Communications, vol. 273, no. 2, pp. 793–798, 2000.
  61. S. M. Gasser and M. M. Cockell, “The molecular biology of the SIR proteins,” Gene, vol. 279, no. 1, pp. 1–16, 2001.
  62. B. Vergnes, D. Sereno, N. Madjidian-Sereno, J.-L. Lemesre, and A. Ouaissi, “Cytoplasmic SIR2 homologue overexpression promotes survival of Leishmania parasites by preventing programmed cell death,” Gene, vol. 296, no. 1-2, pp. 139–150, 2002.
  63. K. Zemzoumi, D. Sereno, C. François, E. Guilvard, J.-L. Lemesre, and A. Ouaissi, “Leishmania major: cell type dependent distribution of a 43 kDa antigen related to silent information regulatory-2 protein family,” Biology of the Cell, vol. 90, no. 3, pp. 239–245, 1998.
  64. R. Silvestre, A. Cordeiro-da-Silva, J. Tavares, D. Sereno, and A. Ouaissi, “Leishmania cytosolic silent information regulatory protein 2 deacetylase induces murine B-cell differentiation and in vivo production of specific antibodies,” Immunology, vol. 119, no. 4, pp. 529–540, 2006.
  65. A. Cordeiro-da-Silva, L. Cardoso, N. Araújo, et al., “Identification of antibodies to Leishmania silent information regulatory 2 (SIR2) protein homologue during canine natural infections: pathological implications,” Immunology Letters, vol. 86, no. 2, pp. 155–162, 2003.
  66. N. Santarém, A. Tomás, A. Ouaissi, et al., “Antibodies against a Leishmania infantum peroxiredoxin as a possible marker for diagnosis of visceral leishmaniasis and for monitoring the efficacy of treatment,” Immunology Letters, vol. 101, no. 1, pp. 18–23, 2005.
  67. P. F. P. Pimenta, E. M. B. Saraiva, and D. L. Sacks, “The comparative fine structure and surface glycoconjugate expression of three life stages of Leishmania major,” Experimental Parasitology, vol. 72, no. 2, pp. 191–204, 1991.
  68. M. A. J. Ferguson, “The surface glycoconjugates of trypanosomatid parasites,” Philosophical Transactions of the Royal Society B, vol. 352, no. 1359, pp. 1295–1302, 1997.
  69. M. J. McConville and J. M. Blackwell, “Developmental changes in the glycosylated phosphatidylinositols of Leishmania donovani. Characterization of the promastigote and amastigote glycolipids,” The Journal of Biological Chemistry, vol. 266, no. 23, pp. 15170–15179, 1991.
  70. J. Bouvier, R. J. Etges, and C. Bordier, “Identification and purification of membrane and soluble forms of the major surface protein of Leishmania promastigotes,” The Journal of Biological Chemistry, vol. 260, no. 29, pp. 15504–15509, 1985.
  71. C. Yao, J. E. Donelson, and M. E. Wilson, “The major surface protease (MSP or GP63) of Leishmania sp. Biosynthesis, regulation of expression, and function,” Molecular and Biochemical Parasitology, vol. 132, no. 1, pp. 1–16, 2003.
  72. R. Etges, J. Bouvier, and C. Bordier, “The major surface protein of Leishmania promastigotes is a protease,” The Journal of Biological Chemistry, vol. 261, no. 20, pp. 9098–9101, 1986.
  73. C. Bordier, “The promastigote surface protease of Leishmania,” Parasitology Today, vol. 3, no. 5, pp. 151–153, 1987.
  74. J. Bouvier, R. Etges, and C. Bordier, “Identification of the promastigote surface protease in seven species of Leishmania,” Molecular and Biochemical Parasitology, vol. 24, no. 1, pp. 73–79, 1987.
  75. E. A. Okong'o-Odera, J. A. L. Kurtzhals, A. S. Hey, and A. Kharazmi, “Measurement of serum antibodies against native Leishmania gp63 distinguishes between ongoing and previous L. donovani infection,” APMIS, vol. 101, no. 8, pp. 642–646, 1993.
  76. W. G. Shreffler, J. M. Burns, Jr., R. Badaró, et al., “Antibody responses of visceral leishmaniasis patients to gp63, a major surface glycoprotein of Leishmania species,” Journal of Infectious Diseases, vol. 167, no. 2, pp. 426–430, 1993.
  77. G. Morales, G. Carrillo, J. M. Requena, et al., “Mapping of the antigenic determinants of the Leishmania infantum gp63 protein recognized by antibodies elicited during canine visceral leishmaniasis,” Parasitology, vol. 114, part 6, pp. 507–516, 1997.
  78. T. Sanyal, D. K. Ghosh, and D. Sarkar, “Immunoblotting identifies an antigen recognized by anti gp63 in the immune complexes of Indian kala-azar patient sera,” Molecular and Cellular Biochemistry, vol. 130, no. 1, pp. 11–17, 1994.
  79. T. Chakraborti, D. Sarkar, and D. K. Ghosh, “Immune complex antigens as a tool in serodiagnosis of kala-azar,” Molecular and Cellular Biochemistry, vol. 253, no. 1-2, pp. 191–198, 2003.
  80. E. W. Mohareb, H. A. Hanafi, E. M. Mikhail, S. M. Presley, and R. Batchelor, “Evaluation of an indirect immunofluorescence assay for the detection of Leishmania promastigotes and amastigotes in sand flies and lesion fluid aspirates,” Journal of the Egyptian Society of Parasitology, vol. 28, no. 2, pp. 313–321, 1998.
  81. L. P. Kahl, R. Lelchuk, C. A. Scott, and J. Beesley, “Characterization of Leishmania major antigen-liposomes that protect BALB/c mice against cutaneous leishmaniasis,” Infection and Immunity, vol. 58, no. 10, pp. 3233–3241, 1990.
  82. D. G. Russell and J. Alexander, “Effective immunization cutaneous leishmaniasis with defined membrane antigens reconsituted into liposomes,” The Journal of Immunology, vol. 140, no. 4, pp. 1274–1279, 1988.
  83. F. Afrin, R. Rajesh, K. Anam, M. Gopinath, S. Pal, and N. Ali, “Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice,” Infection and Immunity, vol. 70, no. 12, pp. 6697–6706, 2002.
  84. S. Bhowmick, R. Ravindran, and N. Ali, “gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani,” Infection and Immunity, vol. 76, no. 3, pp. 1003–1015, 2008.
  85. M. R. Jaafari, A. Ghafarian, A. Farrokh-Gisour, et al., “Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice,” Vaccine, vol. 24, no. 29-30, pp. 5708–5717, 2006.
  86. M. R. Jaafari, A. Badiee, A. Khamesipour, et al., “The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome,” Vaccine, vol. 25, no. 32, pp. 6107–6117, 2007.
  87. D. M. Yang, N. Fairweather, L. L. Button, W. R. McMaster, L. P. Kahl, and F. Y. Liew, “Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis,” The Journal of Immunology, vol. 145, no. 7, pp. 2281–2285, 1990.
  88. S. Abdelhak, H. Louzir, J. Timm, et al., “Recombinant BCG expressing the Leishmania surface antigen gp63 induces protective immunity against Leishmania major infection in BALB/c mice,” Microbiology, vol. 141, part 7, pp. 1585–1592, 1995.
  89. N. D. Connell, E. Medina-Acosta, W. R. McMaster, B. R. Bloom, and D. G. Russell, “Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 24, pp. 11473–11477, 1993.
  90. C. W. Xu, J. C. Hines, M. L. Engel, D. G. Russell, and D. S. Ray, “Nucleus-encoded histone H1-like proteins are associated with kinetoplast DNA in the trypanosomatid Crithidia fasciculata,” Molecular and Cellular Biology, vol. 16, no. 2, pp. 564–576, 1996.
  91. S. Frankenburg, O. Axelrod, S. Kutner, et al., “Effective immunization of mice against cutaneous leishmaniasis using an intrinsically adjuvanted synthetic lipopeptide vaccine,” Vaccine, vol. 14, no. 9, pp. 923–929, 1996.
  92. P. Tsagozis, E. Karagouni, and E. Dotsika, “Dendritic cells pulsed with peptides of gp63 induce differential protection against experimental cutaneous leishmaniasis,” International Journal of Immunopathology and Pharmacology, vol. 17, no. 3, pp. 343–352, 2004.
  93. D. McMahon-Pratt, Y. Traub-Cseko, K. L. Lohman, D. D. Rogers, and S. M. Beverley, “Loss of the GP46/M-2 surface membrane glycoprotein gene family in the Leishmania braziliensis complex,” Molecular and Biochemical Parasitology, vol. 50, no. 1, pp. 151–160, 1992.
  94. L. P. Kahl and D. McMahon-Pratt, “Structural and antigenic characterization of a species- and promastigote-specific Leishmania mexicana amazonensis membrane protein,” The Journal of Immunology, vol. 138, no. 5, pp. 1587–1595, 1987.
  95. I. A. Maalej, M. Chenik, H. Louzir, et al., “Comparative evaluation of ELISAs based on ten recombinant or purified Leishmania antigens for the serodiagnosis of Mediterranean visceral leishmaniasis,” The American Journal of Tropical Medicine and Hygiene, vol. 68, no. 3, pp. 312–320, 2003.
  96. C. Boceta, C. Alonso, and A. Jiménez-Ruiz, “Leucine rich repeats are the main epitopes in Leishmania infantum PSA during canine and human visceral leishmaniasis,” Parasite Immunology, vol. 22, no. 2, pp. 55–62, 2000.
  97. E. Handman, F. M. Symons, T. M. Baldwin, J. M. Curtis, and J.-P. Y. Scheerlinck, “Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response,” Infection and Immunity, vol. 63, no. 11, pp. 4261–4267, 1995.
  98. A. Sjölander, T. M. Baldwin, J. M. Curtis, and E. Handman, “Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to Leishmaniasis,” The Journal of Immunology, vol. 160, no. 8, pp. 3949–3957, 1998.
  99. A. Sjölander, T. M. Baldwin, J. M. Curtis, K. L. Bengtsson, and E. Handman, “Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection,” Vaccine, vol. 16, no. 20, pp. 2077–2084, 1998.
  100. E. Handman, A. H. Noormohammadi, J. M. Curtis, T. Baldwin, and A. Sjölander, “Therapy of murine cutaneous leishmaniasis by DNA vaccination,” Vaccine, vol. 18, no. 26, pp. 3011–3017, 2000.
  101. E. Dumonteil, R.-S. Maria Jesus, E.-O. Javier, and G.-M. Maria del Rosario, “DNA vaccines induce partial protection against Leishmania mexicana,” Vaccine, vol. 21, no. 17-18, pp. 2161–2168, 2003.
  102. E. Dumonteil, F. Andrade-Narvarez, J. Escobedo-Ortegon, et al., “Comparative study of DNA vaccines encoding various antigens against Leishmania mexicana,” Developments in Biologicals, vol. 104, pp. 135–141, 2000.
  103. D. McMahon-Pratt, D. Rodriguez, J.-R. Rodriguez, et al., “Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection,” Infection and Immunity, vol. 61, no. 8, pp. 3351–3359, 1993.
  104. D. L. Tolson, A. Jardim, L. F. Schnur, et al., “The kinetoplastid membrane protein 11 of Leishmania donovani and African trypanosomes is a potent stimulator of T-lymphocyte proliferation,” Infection and Immunity, vol. 62, no. 11, pp. 4893–4899, 1994.
  105. A. Jardim, V. Funk, R. M. Caprioli, and R. W. Olafson, “Isolation and structural characterization of the Leishmania donovani kinetoplastid membrane protein-11, a major immunoreactive membrane glycoprotein,” Biochemical Journal, vol. 305, part 1, pp. 307–313, 1995.
  106. C. Berberich, J. M. Requena, and C. Alonso, “Cloning of genes and expression and antigenicity analysis of the Leishmania infantum KMP-11 protein,” Experimental Parasitology, vol. 85, no. 1, pp. 105–108, 1997.
  107. J. R. Ramírez, C. Berberich, A. Jaramillo, C. Alonso, and I. D. Vélez, “Molecular and antigenic characterization of the Leishmania (Viannia) panamensis kinetoplastid membrane protein-11,” Memórias do Instituto Oswaldo Cruz, vol. 93, no. 2, pp. 247–254, 1998.
  108. A. T. R. Jensen, S. Gasim, A. Ismail, et al., “Humoral and cellular immune responses to synthetic peptides of the Leishmania donovani kinetoplastid membrane protein-11,” Scandinavian Journal of Immunology, vol. 48, no. 1, pp. 103–109, 1998.
  109. C. Trujillo, R. Ramírez, I. D. Vélez, and C. Berberich, “The humoral immune response to the kinetoplastid membrane protein-11 in patients with American Leishmaniasis and Chagas disease: prevalence of IgG subclasses and mapping of epitopes,” Immunology Letters, vol. 70, no. 3, pp. 203–209, 2000.
  110. S. Passos, L. P. de Carvalho, G. Orge, et al., “Recombinant Leishmania antigens for serodiagnosis of visceral leishmaniasis,” Clinical and Diagnostic Laboratory Immunology, vol. 12, no. 10, pp. 1164–1167, 2005.
  111. A. Jardim, D. L. Tolson, S. J. Turco, T. W. Pearson, and R. W. Olafson, “The Leishmania donovani lipophosphoglycan T lymphocyte-reactive component is a tightly associated protein complex,” The Journal of Immunology, vol. 147, no. 10, pp. 3538–3544, 1991.
  112. E. Carrillo, M. Crusat, J. Nieto, et al., “Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis,” Vaccine, vol. 26, no. 15, pp. 1902–1911, 2008.
  113. R. Basu, S. Bhaumik, J. M. Basu, K. Naskar, T. De, and S. Roy, “Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis,” The Journal of Immunology, vol. 174, no. 11, pp. 7160–7171, 2005.
  114. J. R. Ramírez, K. Gilchrist, S. Robledo, et al., “Attenuated Toxoplasma gondii ts-4 mutants engineered to express the Leishmania antigen KMP-11 elicit a specific immune response in BALB/c mice,” Vaccine, vol. 20, no. 3-4, pp. 455–461, 2001.
  115. P. G. McKean, R. Delahay, P. F. P. Pimenta, and D. F. Smith, “Characterisation of a second protein encoded by the differentially regulated LmcDNA16 gene family of Leishmania major,” Molecular and Biochemical Parasitology, vol. 85, no. 2, pp. 221–231, 1997.
  116. H. M. Flinn, D. Rangarajan, and D. F. Smith, “Expression of a hydrophilic surface protein in infective stages of Leishmania major,” Molecular and Biochemical Parasitology, vol. 65, no. 2, pp. 259–270, 1994.
  117. T. M. Alce, S. Gokool, D. McGhie, S. Stäger, and D. F. Smith, “Expression of hydrophilic surface proteins in infective stages of Leishmania donovani,” Molecular and Biochemical Parasitology, vol. 102, no. 1, pp. 191–196, 1999.
  118. A. T. R. Jensen, S. Gasim, T. Moller, et al., “Serodiagnosis of Leishmania donovani infections: assessment of enzyme-linked immunosorbent assays using recombinant L. donovani gene B protein (GBP) and a peptide sequence of L. donovani GBP,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 93, no. 2, pp. 157–160, 1999.
  119. S. Stäger, D. F. Smith, and P. M. Kaye, “Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis,” The Journal of Immunology, vol. 165, no. 12, pp. 7064–7071, 2000.
  120. J. Moreno, J. Nieto, S. Masina, et al., “Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis,” Vaccine, vol. 25, no. 29, pp. 5290–5300, 2007.
  121. R. Badaró, D. Benson, M. C. Eulálio, et al., “rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis,” The Journal of Infectious Diseases, vol. 173, no. 3, pp. 758–761, 1996.
  122. K. G. J. Pollock, K. S. McNeil, J. C. Mottram, et al., “The Leishmania mexicana cysteine protease, CPB2.8, induces potent Th2 responses,” The Journal of Immunology, vol. 170, no. 4, pp. 1746–1753, 2003.
  123. S. Rafati, A. Nakhaee, T. Taheri, et al., “Expression of cysteine proteinase type I and II of Leishmania infantum and their recognition by sera during canine and human visceral leishmaniasis,” Experimental Parasitology, vol. 103, no. 3-4, pp. 143–151, 2003.
  124. E. Pateraki, R. Portocala, H. Labrousse, and J. L. Guesdon, “Antiactin and antitubulin antibodies in canine visceral leishmaniasis,” Infection and Immunity, vol. 42, no. 2, pp. 496–500, 1983.
  125. K. Zemzoumi, E. Guilvard, D. Sereno, et al., “Cloning of a Leishmania major gene encoding for an antigen with extensive homology to ribosomal protein S3a,” Gene, vol. 240, no. 1, pp. 57–65, 1999.
  126. Y. A. W. Skeiky, D. R. Benson, M. Elwasila, R. Badaro, J. M. Burns, Jr., and S. G. Reed, “Antigens shared by Leishmania species and Trypanosoma cruzi: immunological comparison of the acidic ribosomal P0 proteins,” Infection and Immunity, vol. 62, no. 5, pp. 1643–1651, 1994.
  127. A. M. Montalvo-Álvarez, C. Folgueira, J. Carrión, L. Monzote-Fidalgo, C. Cañavate, and J. M. Requena, “The Leishmania HSP20 is antigenic during natural infections, but, as DNA vaccine, it does not protect BALB/c mice against experimental L. amazonensis infection,” Journal of Biomedicine and Biotechnology, vol. 2008, Article ID 695432, 9 pages, 2008.
  128. J. A. Rey-Ladino, P. B. Joshi, B. Singh, R. Gupta, and N. E. Reiner, “Leishmania major: molecular cloning, sequencing, and expression of the heat shock protein 60 gene reveals unique carboxy terminal peptide sequences,” Experimental Parasitology, vol. 85, no. 3, pp. 249–263, 1997.
  129. L. Quijada, J. M. Requena, M. Soto, and C. Alonso, “During canine viscero-cutaneous leishmaniasis the anti-Hsp70 antibodies are specifically elicited by the parasite protein,” Parasitology, vol. 112, part 3, pp. 277–284, 1996.
  130. R. Larreta, M. Soto, C. Alonso, and J. M. Requena, “Leishmania infantum: gene cloning of the GRP94 homologue, its expression as recombinant protein, and analysis of antigenicity,” Experimental Parasitology, vol. 96, no. 2, pp. 108–115, 2000.
  131. M. Soto, J. M. Requena, L. Quijada, et al., “Antigenicity of the Leishmania infantum histones H2B and H4 during canine viscerocutaneous leishmaniasis,” Clinical & Experimental Immunology, vol. 115, no. 2, pp. 342–349, 1999.
  132. S. Rafati, A.-H. Salmanian, K. Hashemi, C. Schaff, S. Belli, and N. Fasel, “Identification of Leishmania major cysteine proteinases as targets of the immune response in humans,” Molecular and Biochemical Parasitology, vol. 113, no. 1, pp. 35–43, 2001.
  133. N. Khoshgoo, F. Zahedifard, H. Azizi, Y. Taslimi, M. J. Alonso, and S. Rafati, “Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals,” Vaccine, vol. 26, no. 46, pp. 5822–5829, 2008.
  134. J. M. Burns, Jr., W. G. Shreffler, D. R. Benson, H. W. Ghalib, R. Badaro, and S. G. Reed, “Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 2, pp. 775–779, 1993.
  135. M. T. M. Roberts, C. B. Stober, A. N. McKenzie, and J. M. Blackwell, “Interleukin-4 (IL-4) and IL-10 collude in vaccine failure for novel exacerbatory antigens in murine Leishmania major infection,” Infection and Immunity, vol. 73, no. 11, pp. 7620–7628, 2005.
  136. A. Cordeiro-da-Silva, M. C. Borges, E. Guilvard, and A. Ouaissi, “Dual role of the Leishmania major ribosomal protein S3a homologue in regulation of T- and B-cell activation,” Infection and Immunity, vol. 69, no. 11, pp. 6588–6596, 2001.
  137. M. Soto, J. M. Requena, L. Quijada, F. Guzman, M. E. Patarroyo, and C. Alonso, “Identification of the Leishmania infantum P0 ribosomal protein epitope in canine visceral leishmaniasis,” Immunology Letters, vol. 48, no. 1, pp. 23–28, 1995.
  138. M. Soto, J. M. Requena, L. Quijada, et al., “During active viscerocutaneous leishmaniasis the anti-P2 humoral response is specifically triggered by the parasite P proteins,” Clinical & Experimental Immunology, vol. 100, no. 2, pp. 246–252, 1995.
  139. M. J. Levin, M. Vazquez, D. Kaplan, and A. G. Schijman, “The Trypanosoma cruzi ribosomal P protein family: classification and antigenicity,” Parasitology Today, vol. 9, no. 10, pp. 381–384, 1993.
  140. S. Iborra, D. R. Abánades, N. Parody, et al., “The immunodominant T helper 2 (Th2) response elicited in BALB/c mice by the Leishmania LiP2a and LiP2b acidic ribosomal proteins cannot be reverted by strong Th1 inducers,” Clinical & Experimental Immunology, vol. 150, no. 2, pp. 375–385, 2007.
  141. M. Soto, C. Alonso, and J. M. Requena, “The Leishmania infantum acidic ribosomal protein LiP2a induces a prominent humoral response in vivo and stimulates cell proliferation in vitro and interferon-gamma (IFN-γ) production by murine splenocytes,” Clinical & Experimental Immunology, vol. 122, no. 2, pp. 212–218, 2000.
  142. M. Soto, J. M. Requena, L. Quijada, and C. Alonso, “Specific serodiagnosis of human leishmaniasis with recombinant Leishmania P2 acidic ribosomal proteins,” Clinical and Diagnostic Laboratory Immunology, vol. 3, no. 4, pp. 387–391, 1996.
  143. K. Elkon, S. Skelly, A. Parnassa, et al., “Identification and chemical synthesis of a ribosomal protein antigenic determinant in systemic lupus erythematosus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 19, pp. 7419–7423, 1986.
  144. C. Mayer, U. Appenzeller, H. Seelbach, et al., “Humoral and cell-mediated autoimmune reactions to human acidic ribosomal P2 protein in individuals sensitized to Aspergillus fumigatus P2 protein,” Journal of Experimental Medicine, vol. 189, no. 9, pp. 1507–1512, 1999.
  145. Y. A. W. Skeiky, D. R. Benson, M. Parsons, K. B. Elkon, and S. G. Reed, “Cloning and expression of Trypanosoma cruzi ribosomal protein P0 and epitope analysis of anti-P0 autoantibodies in Chagas' disease patients,” Journal of Experimental Medicine, vol. 176, no. 1, pp. 201–211, 1992.
  146. S. Iborra, M. Soto, J. Carrión, et al., “The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice,” Infection and Immunity, vol. 71, no. 11, pp. 6562–6572, 2003.
  147. S. Iborra, J. Carrión, C. Anderson, C. Alonso, D. Sacks, and M. Soto, “Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice,” Infection and Immunity, vol. 73, no. 9, pp. 5842–5852, 2005.
  148. E. Arndt and C. Weigel, “Nucleotide sequence of the genes encoding the L11, L1, L10 and L12 equivalent ribosomal proteins from the archaebacterium Halobacterium marismortui,” Nucleic Acids Research, vol. 18, no. 5, p. 1285, 1990.
  149. D. B. Young, “Heat-shock proteins: immunity and autoimmunity,” Current Opinion in Immunology, vol. 4, no. 4, pp. 396–400, 1992.
  150. C. Folgueira and J. M. Requena, “A postgenomic view of the heat shock proteins in kinetoplastids,” FEMS Microbiology Reviews, vol. 31, no. 4, pp. 359–377, 2007.
  151. B. J. Celeste, S. O. Angel, L. G. M. Castro, M. Gidlund, and H. Goto, “Leishmania infantum heat shock protein 83 for the serodiagnosis of tegumentary leishmaniasis,” Brazilian Journal of Medical and Biological Research, vol. 37, no. 11, pp. 1591–1593, 2004.
  152. S. K. Gupta, B. S. Sisodia, S. Sinha, et al., “Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of Leishmania donovani promastigotes,” Proteomics, vol. 7, no. 5, pp. 816–823, 2007.
  153. A. Descoteaux, H. A. Avila, K. Zhang, S. J. Turco, and S. M. Beverley, “Leishmania LPG3 encodes a GRP94 homolog required for phosphoglycan synthesis implicated in parasite virulence but not viability,” The EMBO Journal, vol. 21, no. 17, pp. 4458–4469, 2002.
  154. R. Larreta, F. Guzman, M. E. Patarroyo, C. Alonso, and J. M. Requena, “Antigenic properties of the Leishmania infantum GRP94 and mapping of linear B-cell epitopes,” Immunology Letters, vol. 80, no. 3, pp. 199–205, 2002.
  155. L. Quijada, J. M. Requena, M. Soto, and C. Alonso, “Analysis of the antigenic properties of the L. infantum Hsp70: design of synthetic peptides for specific serodiagnosis of human leishmaniasis,” Immunology Letters, vol. 63, no. 3, pp. 169–174, 1998.
  156. A. I. Zurita, J. Rodríguez, J. E. Piñero, et al., “Cloning and characterization of the Leishmania (Viannia) braziliensis HSP70 gene. Diagnostic use of the C-terminal fragment rlb70(513–663),” Journal of Parasitology, vol. 89, no. 2, pp. 372–378, 2003.
  157. P. Echeverria, G. Dran, G. Pereda, et al., “Analysis of the adjuvant effect of recombinant Leishmania infantum Hsp83 protein as a tool for vaccination,” Immunology Letters, vol. 76, no. 2, pp. 107–110, 2001.
  158. A. I. Rico, G. Del Real, M. Soto, et al., “Characterization of the immunostimulatory properties of Leishmania infantum HSP70 by fusion to the Escherichia coli maltose-binding protein in normal and nu/nu BALB/c mice,” Infection and Immunity, vol. 66, no. 1, pp. 347–352, 1998.
  159. S. Rafati, E. Gholami, N. Hassani, et al., “Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients,” Vaccine, vol. 25, no. 21, pp. 4159–4169, 2007.
  160. J. R. Webb, A. Campos-Neto, Y. A. W. Skeiky, and S. G. Reed, “Molecular characterization of the heat-inducible LmSTI1 protein of Leishmania major,” Molecular and Biochemical Parasitology, vol. 89, no. 2, pp. 179–193, 1997.
  161. A. Campos-Neto, R. Porrozzi, K. Greeson, et al., “Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease,” Infection and Immunity, vol. 69, no. 6, pp. 4103–4108, 2001.
  162. A. Campos-Neto, J. R. Webb, K. Greeson, R. N. Coler, Y. A. W. Skeiky, and S. G. Reed, “Vaccination with plasmid DNA encoding TSA/LmSTI1 Leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice,” Infection and Immunity, vol. 70, no. 6, pp. 2828–2836, 2002.
  163. A. Badiee, M. R. Jaafari, A. Samiei, D. Soroush, and A. Khamesipour, “Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice,” Clinical and Vaccine Immunology, vol. 15, no. 4, pp. 668–674, 2008.
  164. M. Soto, J. M. Requena, L. Quijada, et al., “Mapping of the linear antigenic determinants from the Leishmania infantum histone H2A recognized by sera from dogs with leishmaniasis,” Immunology Letters, vol. 48, no. 3, pp. 209–214, 1995.
  165. M. Soto, J. M. Requena, L. Quijada, et al., “Characterization of the antigenic determinants of the Leishmania infantum histone H3 recognized by antibodies elicited during canine visceral leishmaniasis,” Clinical & Experimental Immunology, vol. 106, no. 3, pp. 454–461, 1996.
  166. Y. Montoya, C. Leon, M. Talledo, et al., “Recombinant antigens for specific and sensitive serodiagnosis of Latin American tegumentary leishmaniasis,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 91, no. 6, pp. 674–676, 1997.
  167. L. P. de Carvalho, M. Soto, S. Jerônimo, et al., “Characterization of the immune response to Leishmania infantum recombinant antigens,” Microbes and Infection, vol. 5, no. 1, pp. 7–12, 2003.
  168. S. Iborra, M. Soto, J. Carrión, C. Alonso, and J. M. Requena, “Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis,” Vaccine, vol. 22, no. 29-30, pp. 3865–3876, 2004.
  169. J. Carrión, A. Nieto, M. Soto, and C. Alonso, “Adoptive transfer of dendritic cells pulsed with Leishmania infantum nucleosomal histones confers protection against cutaneous leishmaniosis in BALB/c mice,” Microbes and Infection, vol. 9, no. 6, pp. 735–743, 2007.
  170. J. Carrión, C. Folgueira, and C. Alonso, “Transitory or long-lasting immunity to Leishmania major infection: the result of immunogenicity and multicomponent properties of histone DNA vaccines,” Vaccine, vol. 26, no. 9, pp. 1155–1165, 2008.
  171. J. Carrión, C. Folgueira, and C. Alonso, “Immunization strategies against visceral leishmaniosis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells,” Vaccine, vol. 26, no. 20, pp. 2537–2544, 2008.
  172. M. Chenik, H. Louzir, H. Ksontini, A. Dilou, I. Abdmouleh, and K. Dellagi, “Vaccination with the divergent portion of the protein histone H2B of Leishmania protects susceptible BALB/c mice against a virulent challenge with Leishmania major,” Vaccine, vol. 24, no. 14, pp. 2521–2529, 2006.
  173. D. Smirlis, S. N. Bisti, E. Xingi, G. Konidou, M. Thiakaki, and K. P. Soteriadou, “Leishmania histone H1 overexpression delays parasite cell-cycle progression, parasite differentiation and reduces Leishmania infectivity in vivo,” Molecular Microbiology, vol. 60, no. 6, pp. 1457–1473, 2006.
  174. F. T. Papageorgiou and K. P. Soteriadou, “Expression of a novel Leishmania gene encoding a histone H1-like protein in Leishmania major modulates parasite infectivity in vitro,” Infection and Immunity, vol. 70, no. 12, pp. 6976–6986, 2002.
  175. N. Solioz, U. Blum-Tirouvanziam, R. Jacquet, et al., “The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis,” Vaccine, vol. 18, no. 9-10, pp. 850–859, 1999.
  176. S. Masina, M. M. Gicheru, S. O. Demotz, and N. J. Fasel, “Protection against cutaneous leishmaniasis in outbred vervet monkeys using a recombinant histone H1 antigen,” The Journal of Infectious Diseases, vol. 188, no. 8, pp. 1250–1257, 2003.
  177. J. H. McKerrow, E. Sun, P. J. Rosenthal, and J. Bouvier, “The proteases and pathogenicity of parasitic protozoa,” Annual Review of Microbiology, vol. 47, pp. 821–853, 1993.
  178. J. A. Sakanari, S. A. Nadler, V. J. Chan, J. C. Engel, C. Leptak, and J. Bouvier, “Leishmania major: comparison of the cathepsin L- and B-like cysteine protease genes with those of other trypanosomatids,” Experimental Parasitology, vol. 85, no. 1, pp. 63–76, 1997.
  179. J. C. Mottram, D. R. Brooks, and G. H. Coombs, “Roles of cysteine proteinases of trypanosomes and Leishmania in host-parasite interactions,” Current Opinion in Microbiology, vol. 1, no. 4, pp. 455–460, 1998.
  180. J. C. Mottram, A. E. Souza, J. E. Hutchison, R. Carter, M. J. Frame, and G. H. Coombs, “Evidence from disruption of the lmcpb gene array of Leishmania mexicana that cysteine proteinases are virulence factors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 12, pp. 6008–6013, 1996.
  181. L. U. Buxbaum, H. Denise, G. H. Coombs, J. Alexander, J. C. Mottram, and P. Scott, “Cysteine protease B of Leishmania mexicana inhibits host Th1 responses and protective immunity,” The Journal of Immunology, vol. 171, no. 7, pp. 3711–3717, 2003.
  182. J. Alexander and K. Bryson, “T helper (h)1/Th2 and Leishmania: paradox rather than paradigm,” Immunology Letters, vol. 99, no. 1, pp. 17–23, 2005.
  183. S. de Souza Dias, P. H. da Costa Pinheiro, S. Katz, M. R. Machado dos Santos, and C. L. Barbiéri, “A recombinant cysteine proteinase from Leishmania (Leishmania) chagasi suitable for serodiagnosis of American visceral leishmaniasis,” The American Journal of Tropical Medicine and Hygiene, vol. 72, no. 2, pp. 126–132, 2005.
  184. H. Pascalis, A. Lavergne, E. Bourreau, et al., “Th1 cell development induced by cysteine proteinases A and B in localized cutaneous leishmaniasis due to Leishmania guyanensis,” Infection and Immunity, vol. 71, no. 5, pp. 2924–2926, 2003.
  185. A. Zadeh-Vakili, T. Taheri, Y. Taslimi, F. Doustdari, A.-H. Salmanian, and S. Rafati, “Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis,” Vaccine, vol. 22, no. 15-16, pp. 1930–1940, 2004.
  186. P. H. da Costa Pinheiro, S. de Souza Dias, K. Dantas Eulálio, I. L. Mendonça, S. Katz, and C. L. Barbiéri, “Recombinant cysteine proteinase from Leishmania (Leishmania) chagasi implicated in human and dog T-cell responses,” Infection and Immunity, vol. 73, no. 6, pp. 3787–3789, 2005.
  187. S. Rafati, A.-H. Salmanian, T. Taheri, M. Vafa, and N. Fasel, “A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major,” Vaccine, vol. 19, no. 25-26, pp. 3369–3375, 2001.
  188. S. Rafati, A. Kariminia, S. Seyde-Eslami, M. Narimani, T. Taheri, and M. Lebbatard, “Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon gamma producing CD8+ T lymphocyte activation,” Vaccine, vol. 20, no. 19-20, pp. 2439–2447, 2002.
  189. S. Rafati, F. Zahedifard, and F. Nazgouee, “Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis,” Vaccine, vol. 24, no. 12, pp. 2169–2175, 2006.
  190. S. Rafati, A. Nakhaee, T. Taheri, et al., “Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum,” Vaccine, vol. 23, no. 28, pp. 3716–3725, 2005.
  191. J. Poot, K. Spreeuwenberg, S. J. Sanderson, et al., “Vaccination with a preparation based on recombinant cysteine peptidases and canine IL-12 does not protect dogs from infection with Leishmania infantum,” Vaccine, vol. 24, no. 14, pp. 2460–2468, 2006.
  192. P. Probst, Y. A. W. Skeiky, M. Steeves, A. Gervassi, K. H. Grabstein, and S. G. Reed, “A Leishmania protein that modulates interleukin (IL)-12, IL-10 and tumor necrosis factor-α production and expression of B7-1 in human monocyte-derived antigen-presenting cells,” European Journal of Immunology, vol. 27, no. 10, pp. 2634–2642, 1997.
  193. Y. A. W. Skeiky, M. Kennedy, D. Kaufman, et al., “LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile,” The Journal of Immunology, vol. 161, no. 11, pp. 6171–6179, 1998.
  194. M. M. Borges, A. Campos-Neto, P. Sleath, et al., “Potent stimulation of the innate immune system by a Leishmania brasiliensis recombinant protein,” Infection and Immunity, vol. 69, no. 9, pp. 5270–5277, 2001.
  195. P. Launois, I. Maillard, S. Pingel, et al., “IL-4 rapidly produced by Vβ4 V α8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice,” Immunity, vol. 6, no. 5, pp. 541–549, 1997.
  196. S. Gurunathan, D. L. Sacks, D. R. Brown, et al., “Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major,” Journal of Experimental Medicine, vol. 186, no. 7, pp. 1137–1147, 1997.
  197. V. Julia, M. Rassoulzadegan, and N. Glaichenhaus, “Resistance to Leishmania major induced by tolerance to a single antigen,” Science, vol. 274, no. 5286, pp. 421–423, 1996.
  198. S. Ben Hadj Ahmed, C. Bahloul, C. Robbana, S. Askri, and K. Dellagi, “A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major,” Vaccine, vol. 22, no. 13-14, pp. 1631–1639, 2004.
  199. N. Soussi, H. Saklani-Jusforgues, J.-H. Colle, G. Milon, N. Glaichenhaus, and P. L. Goossens, “Effect of intragastric and intraperitoneal immunisation with attenuated and wild-type LACK-expressing Listeria monocytogenes on control of murine Leishmania major infection,” Vaccine, vol. 20, no. 21-22, pp. 2702–2712, 2002.
  200. R. M. Gonzalo, J. R. Rodríguez, D. Rodríguez, G. González-Aseguinolaza, V. Larraga, and M. Esteban, “Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36,” Microbes and Infection, vol. 3, no. 9, pp. 701–711, 2001.
  201. R. M. Gonzalo, G. del Real, J. R. Rodriguez, et al., “A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis,” Vaccine, vol. 20, no. 7-8, pp. 1226–1231, 2002.
  202. E. Pérez-Jiménez, G. Kochan, M. M. Gherardi, and M. Esteban, “MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis,” Microbes and Infection, vol. 8, no. 3, pp. 810–822, 2006.
  203. E. A .F. Coelho, C. A. P. Tavares, F. A. A. Carvalho, et al., “Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection,” Infection and Immunity, vol. 71, no. 7, pp. 3988–3994, 2003.
  204. T. Okuno, M. Takeuchi, Y. Matsumoto, H. Otsuka, and Y. Matsumoto, “Pretreatment of Leishmania homologue of receptors for activated C kinase (LACK) promotes disease progression caused by Leishmania amazonensis,” Experimental Animals, vol. 51, no. 4, pp. 335–341, 2002.
  205. E. F. Pinto, R. O. Pinheiro, A. Rayol, V. Larraga, and B. Rossi-Bergmann, “Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK,” Infection and Immunity, vol. 72, no. 8, pp. 4521–4527, 2004.
  206. P. C. Melby, J. Yang, W. Zhao, L. E. Perez, and J. Cheng, “Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis,” Infection and Immunity, vol. 69, no. 8, pp. 4719–4725, 2001.
  207. E. A. Marques-da-Silva, E. A .F. Coelho, D. C. O. Gomes, et al., “Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-γ production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge,” Parasitology Research, vol. 98, no. 1, pp. 67–74, 2005.
  208. M. J. Ramiro, J. J. Zárate, T. Hanke, et al., “Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK,” Vaccine, vol. 21, no. 19-20, pp. 2474–2484, 2003.
  209. I. Ramos, A. Alonso, J. M. Marcen, et al., “Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response,” Vaccine, vol. 26, no. 3, pp. 333–344, 2008.
  210. B. Dondji, E. Pérez-Jimenez, K. Goldsmith-Pestana, M. Esteban, and D. McMahon-Pratt, “Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis,” Infection and Immunity, vol. 73, no. 8, pp. 5286–5289, 2005.
  211. W.-W. Zhang, H. Charest, E. Ghedin, and G. Matlashewski, “Identification and overexpression of the A2 amastigote-specific protein in Leishmania donovani,” Molecular and Biochemical Parasitology, vol. 78, no. 1-2, pp. 79–90, 1996.
  212. D. R. A. Martins, S. M. B. Jeronimo, J. E. Donelson, and M. E. Wilson, “Leishmania chagasi T-cell antigens identified through a double library screen,” Infection and Immunity, vol. 74, no. 12, pp. 6940–6948, 2006.
  213. E. Ghedin, W. W. Zhang, H. Charest, S. Sundar, R. T. Kenney, and G. Matlashewski, “Antibody response against a Leishmania donovani amastigote-stage-specific protein in patients with visceral leishmaniasis,” Clinical and Diagnostic Laboratory Immunology, vol. 4, no. 5, pp. 530–535, 1997.
  214. F. A. A. Carvalho, H. Charest, C. A. P. Tavares, et al., “Diagnosis of American visceral leishmaniasis in humans and dogs using the recombinant Leishmania donovani A2 antigen,” Diagnostic Microbiology and Infectious Disease, vol. 43, no. 4, pp. 289–295, 2002.
  215. A. Ghosh, S. Labrecque, and G. Matlashewski, “Protection against Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response,” Vaccine, vol. 19, no. 23-24, pp. 3169–3178, 2001.
  216. A. Ghosh, W. W. Zhang, and G. Matlashewski, “Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections,” Vaccine, vol. 20, no. 1-2, pp. 59–66, 2001.
  217. A. P. Fernandes, M. M. S. Costa, E. A. F. Coelho, et al., “Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein,” Vaccine, vol. 26, no. 46, pp. 5888–5895, 2008.
  218. S. F. Guimarães Carvalho, E. M. Lemos, R. Corey, and R. Dietze, “Performance of recombinant K39 antigen in the diagnosis of Brazilian visceral leishmaniasis,” The American Journal of Tropical Medicine and Hygiene, vol. 68, no. 3, pp. 321–324, 2003.
  219. F. J. Medrano, C. Cañavate, M. Leal, C. Rey, E. Lissen, and J. Alvar, “The role of serology in the diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type- 1,” The American Journal of Tropical Medicine and Hygiene, vol. 59, no. 1, pp. 155–162, 1998.
  220. S. Singh, V. Kumari, and N. Singh, “Predicting kala-azar disease manifestations in asymptomatic patients with latent Leishmania donovani infection by detection of antibody against recombinant K39 antigen,” Clinical and Diagnostic Laboratory Immunology, vol. 9, no. 3, pp. 568–572, 2002.
  221. H. Veeken, K. Ritmeijer, J. Seaman, and R. Davidson, “Comparison of an rK39 dipstick rapid test with direct agglutination test and splenic aspiration for the diagnosis of kala-azar in Sudan,” Tropical Medicine & International Health, vol. 8, no. 2, pp. 164–167, 2003.
  222. E. E. Zijlstra, Y. Nur, P. Desjeux, E. A. G. Khalil, A. M. El-Hassan, and J. Groen, “Diagnosing visceral leishmaniasis with the recombinant K39 strip test: experience from the Sudan,” Tropical Medicine & International Health, vol. 6, no. 2, pp. 108–113, 2001.
  223. R. Porrozzi, M. V. Santos da Costa, A. Teva, et al., “Comparative evaluation of enzyme-linked immunosorbent assays based on crude and recombinant leishmanial antigens for serodiagnosis of symptomatic and asymptomatic Leishmania infantum visceral infections in dogs,” Clinical and Vaccine Immunology, vol. 14, no. 5, pp. 544–548, 2007.
  224. S. O. Toz, K.-P. Chang, Y. Ozbel, and M. Z. Alkan, “Diagnostic value of RK39 dipstick in zoonotic visceral leishmaniasis in Turkey,” Journal of Parasitology, vol. 90, no. 6, pp. 1484–1486, 2004.
  225. R. T. da Costa, J. C. França, W. Mayrink, E. Nascimento, O. Genaro, and A. Campos-Neto, “Standardization of a rapid immunochromatographic test with the recombinant antigens K39 and K26 for the diagnosis of canine visceral leishmaniasis,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 97, no. 6, pp. 678–682, 2003.
  226. D. Otranto, P. Paradies, M. Sasanelli, et al., “Recombinant K39 dipstick immunochromatographic test: a new tool for the serodiagnosis of canine leishmaniasis,” Journal of Veterinary Diagnostic Investigation, vol. 17, no. 1, pp. 32–37, 2005.
  227. A. Dey, P. Sharma, N. S. Redhu, and S. Singh, “Kinesin motor domain of Leishmania donovani as a future vaccine candidate,” Clinical and Vaccine Immunology, vol. 15, no. 5, pp. 836–842, 2008.
  228. Y. Belkaid, S. Mendez, R. Lira, N. Kadambi, G. Milon, and D. Sacks, “A natural model of Leishmania major infection reveals a prolonged “silent” phase of parasite amplification in the skin before the onset of lesion formation and immunity,” The Journal of Immunology, vol. 165, no. 2, pp. 969–977, 2000.
  229. S. Méndez, S. Gurunathan, S. Kamhawi, et al., “The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge,” The Journal of Immunology, vol. 166, no. 8, pp. 5122–5128, 2001.
  230. R. T. Fujiwara, A. M. Vale, J. C. França da Silva, et al., “Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis,” Veterinary Research, vol. 36, no. 5-6, pp. 827–838, 2005.
  231. Y. A. W. Skeiky, R. N. Coler, M. Brannon, et al., “Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL® adjuvant,” Vaccine, vol. 20, no. 27-28, pp. 3292–3303, 2002.
  232. R. N. Coler, Y. A. W. Skeiky, K. Bernards, et al., “Immunization with a polyprotein vaccine consisting of the T-cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis,” Infection and Immunity, vol. 70, no. 8, pp. 4215–4225, 2002.
  233. R. N. Coler, Y. Goto, L. Bogatzki, V. Raman, and S. G. Reed, “Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells,” Infection and Immunity, vol. 75, no. 9, pp. 4648–4654, 2007.
  234. A. Boarino, A. Scalone, L. Gradoni, et al., “Development of recombinant chimeric antigen expressing immunodominant B epitopes of Leishmania infantum for serodiagnosis of visceral leishmaniasis,” Clinical and Diagnostic Laboratory Immunology, vol. 12, no. 5, pp. 647–653, 2005.
  235. M. Soto, J. M. Requena, L. Quijada, and C. Alonso, “Multicomponent chimeric antigen for serodiagnosis of canine visceral leishmaniasis,” Journal of Clinical Microbiology, vol. 36, no. 1, pp. 58–63, 1998.
  236. N. Parody, M. Soto, J. M. Requena, and C. Alonso, “Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from Leishmania infantum. A CpG + Q mix protects Balb/c mice from infection,” Parasite Immunology, vol. 26, no. 6-7, pp. 283–293, 2004.
  237. I. Molano, M. García Alonso, C. Mirón, et al., “A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum,” Veterinary Immunology and Immunopathology, vol. 92, no. 1-2, pp. 1–13, 2003.
  238. K.-P. Chang and B. S. McGwire, “Molecular determinants and regulation of Leishmania virulence,” Kinetoplastid Biology and Disease, vol. 1, article 1, pp. 1–7, 2002.
  239. K.-P. Chang, S. G. Reed, B. S. McGwire, and L. Soong, “Leishmania model for microbial virulence: the relevance of parasite multiplication and pathoantigenicity,” Acta Tropica, vol. 85, no. 3, pp. 375–390, 2003.